ADHD

AZSTARYS is now available for treating ADHD

July 22, 2021

AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is available for prescription to help provide rapid and extended duration of attention-deficit/hyperactivity disorder (ADHD) symptoms.

Participation in after-school activities decreases ADHD severity

July 01, 2021

A study examines the effect of after-school activity participation on a child's attention-deficit/hyperactivity disorder (ADHD) severity.

Study examines alternatives for preschool ADHD medications

June 09, 2021

Stimulants are recommended as the first-line treatment for attention-deficit/hyperactivity disorder (ADHD). A study examines whether α2-adrenergic agonists could be effective as well.

Promoting face covering through positive reinforcement

May 21, 2021

A study examines if promoting positive behaviors including masking leads to improved face covering in children with autism spectrum disorder and/or attention-deficit/hyperactivity disorder.

FDA approves non-stimulant Qelbree to treat ADHD

April 06, 2021

The US Food and Drug Administration (FDA) approves first novel non-stimulant medication to treat attention-deficit/hyperactivity disorder (ADHD) in children in a decade.

Examining ADHD disparities due to race and ethnicity

March 09, 2021

Unfortunately, disparities in health care are nothing unusual. A report examines if there are disparities in attention-deficit/hyperactivity disorder (ADHD) diagnosis and treatment due to race and ethnicity.

Is there a link between ADHD and maternal autoimmune disease?

January 22, 2021

A new study examines whether maternal autoimmune diseases are linked to attention-deficit/hyperactivity disorder (ADHD).

The Future of the ADHD Treatment Landscape

December 03, 2020

Stimulant Abuse in Pediatric ADHD Populations

December 03, 2020

Unmet Needs in Pediatric ADHD Management

December 03, 2020